This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nguyen-Yamamoto, L. Articles by D’amour, P. Search for Related Content PubMed PubMed Citation Articles by Nguyen-Yamamoto, L. Articles by D’amour, P.

Synthetic Carboxyl-Terminal Fragments of Parathyroid Hormone (PTH) Decrease Ionized Calcium Concentration in Rats by Acting on a Receptor Different from the PTH/PTH-Related Peptide Receptor

Centre de Recherche, Centre Hospitalier de l’Université de Montréal, Hôpital Saint-Luc, et Départements de Médecine et Biochimie (R.L.), Université de Montréal, Montréal, Québec, Canada H2X 1P1

Address all correspondence and requests for reprints to: Pierre D’Amour, M.D., Centre de Recherche, Centre Hospitalier de l’Université de Montréal, Hôpital Saint-Luc, 264 René Lévesque boulevard East, Montréal, Québec, Canada H2X 1P1. E-mail: rechcalcium{at}ssss.gouv.qc.ca

Even if the carboxyl-terminal (C-) fragments/intact (I-) PTH ratio is tightly regulated by the ionized calcium (Ca²⁺) concentration in humans and animals, in health and in disease, the physiological roles of C-PTH fragments and of the C-PTH receptor remain elusive. To explore these issues, we studied the influence of synthetic C-PTH peptides of various lengths on Ca²⁺ concentration and on the calcemic response to human (h) PTH-(1–34) and hPTH-(1–84) in anesthetized thyroparathyroidectomized (TPTX) rats. We also looked at the capacity of these PTH preparations to react with the PTH/PTHrP receptor and with a receptor for the carboxyl (C)-terminal portion of PTH (C-PTH receptor) in rat osteosarcoma cells, ROS 17/2.8. The Ca²⁺ concentration was reduced by 0.19 ± 0.03 mmol/liter over 2 h in all TPTX groups. Infusion of solvent over 2 more h had no further effect on the Ca²⁺ concentration (-0.01 ± 0.01 mmol/liter), whereas infusion of hPTH-(7–84) or a fragment mixture [10% hPTH-(7–84) and 45% each of hPTH-(39–84) and hPTH-(53–84)] 10 nmol/h further decreased the Ca²⁺ concentration by 0.18 ± 0.02 (P < 0.001) and 0.07 ± 0.04 mmol/liter (P < 0.001), respectively. Infusion of hPTH-(1–84) or hPTH-(1–34) (1 nmol/h) increased the Ca²⁺ concentration by 0.16 ± 0.03 (P < 0.001) and 0.19 ± 0.03 mmol/liter (P < 0.001), respectively. Adding hPTH-(7–84) (10 nmol/h) to these preparations prevented the calcemic response and maintained Ca²⁺ concentrations equal to or below levels observed in TPTX animals infused with solvent alone. Adding the fragment mixture (10 nmol/h) to hPTH-(1–84) did not prevent a normal calcemic response, but partially blocked the response to hPTH-(1–34), and more than 3 nmol/h hPTH-(7–84) prevented it. Both hPTH-(1–84) and hPTH-(1–34) stimulated cAMP production in ROS 17/2.8 clonal cells, whereas hPTH-(7–84) was ineffective in this respect. Both hPTH-(1–84) and hPTH-(1–34) displaced ¹²⁵I-[Nle^8,18,Tyr³⁴]hPTH-(1–34) amide from the PTH/PTHrP receptor, whereas hPTH-(7–84) had no such influence. Both hPTH-(1–84) and hPTH-(7–84) displaced ¹²⁵I-[Tyr³⁴]hPTH-(19–84) from the C-PTH receptor, the former preparation being more potent on a molar basis, whereas hPTH-(1–34) had no effect. These results suggest that C-PTH fragments, particularly hPTH-(7–84), can influence the Ca²⁺ concentration negatively in vivo and limit in such a way the calcemic responses to hPTH-(1–84) and hPTH-(1–34) by interacting with a receptor different from the PTH/PTHrP receptor, possibly a C-PTH receptor.

This article has been cited by other articles:

				R. Eastell, A. Arnold, M. L. Brandi, E. M. Brown, P. D'Amour, D. A. Hanley, D. S. Rao, M. R. Rubin, D. Goltzman, S. J. Silverberg, et al. Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 340 - 350. [Abstract] [Full Text] [PDF]

				C. Valle, M. Rodriguez, R. Santamaria, Y. Almaden, M. E. Rodriguez, S. Canadillas, A. Martin-Malo, and P. Aljama Cinacalcet Reduces the Set Point of the PTH-Calcium Curve J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2430 - 2436. [Abstract] [Full Text] [PDF]

				M. E. McGee-Lawrence, H. V. Carey, and S. W. Donahue Mammalian hibernation as a model of disuse osteoporosis: the effects of physical inactivity on bone metabolism, structure, and strength Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2008; 295(6): R1999 - R2014. [Abstract] [Full Text] [PDF]

				H. H. Malluche, H. Mawad, and M.-C. Monier-Faugere Effects of Treatment of Renal Osteodystrophy on Bone Histology Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S157 - S163. [Abstract] [Full Text] [PDF]

				A. J. Felsenfeld, M. Rodriguez, and E. Aguilera-Tejero Dynamics of Parathyroid Hormone Secretion in Health and Secondary Hyperparathyroidism Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1283 - 1305. [Abstract] [Full Text] [PDF]

				M.-C. Monier-Faugere, H. Mawad, and H. H. Malluche Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal-Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1255 - 1260. [Abstract] [Full Text] [PDF]

				K. J. Martin and E. A. Gonzalez Metabolic Bone Disease in Chronic Kidney Disease J. Am. Soc. Nephrol., March 1, 2007; 18(3): 875 - 885. [Abstract] [Full Text] [PDF]

				J. Jolette, C. E. Wilker, S. Y. Smith, N. Doyle, J. F. Hardisty, A. J. Metcalfe, T. B. Marriott, J. Fox, and D. S. Wells Defining a Noncarcinogenic Dose of Recombinant Human Parathyroid Hormone 1-84 in a 2-Year Study in Fischer 344 Rats Toxicol Pathol, December 1, 2006; 34(7): 929 - 940. [Abstract] [Full Text] [PDF]

				A. A. Selim, M. Mahon, H. Juppner, F. R. Bringhurst, and P. Divieti Role of calcium channels in carboxyl-terminal parathyroid hormone receptor signaling Am J Physiol Cell Physiol, July 1, 2006; 291(1): C114 - C121. [Abstract] [Full Text] [PDF]

				J. Huan, K. Olgaard, L. B. Nielsen, and E. Lewin Parathyroid Hormone 7-84 Induces Hypocalcemia and Inhibits the Parathyroid Hormone 1-84 Secretory Response to Hypocalcemia in Rats with Intact Parathyroid Glands J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1923 - 1930. [Abstract] [Full Text] [PDF]

				P. A. Friedman and W. G. Goodman PTH(1-84)/PTH(7-84): a balance of power Am J Physiol Renal Physiol, May 1, 2006; 290(5): F975 - F984. [Abstract] [Full Text] [PDF]

				T. Arakawa, P. D'Amour, L. Rousseau, J.-H. Brossard, M. Sakai, H. Kasumoto, N. Igaki, T. Goto, T. Cantor, and M. Fukagawa Overproduction and Secretion of a Novel Amino-Terminal Form of Parathyroid Hormone from a Severe Type of Parathyroid Hyperplasia in Uremia Clin. J. Am. Soc. Nephrol., May 1, 2006; 1(3): 525 - 531. [Abstract] [Full Text] [PDF]

				P. D'Amour, A. Rakel, J.-H. Brossard, L. Rousseau, C. Albert, and T. Cantor Acute Regulation of Circulating Parathyroid Hormone (PTH) Molecular Forms by Calcium: Utility of PTH Fragments/PTH(1-84) Ratios Derived from Three Generations of PTH Assays J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 283 - 289. [Abstract] [Full Text] [PDF]

				J. T Potts Parathyroid hormone: past and present J. Endocrinol., December 1, 2005; 187(3): 311 - 325. [Abstract] [Full Text] [PDF]

				P. Divieti, A. I. Geller, G. Suliman, H. Juppner, and F. R. Bringhurst Receptors Specific for the Carboxyl-Terminal Region of Parathyroid Hormone on Bone-Derived Cells: Determinants of Ligand Binding and Bioactivity Endocrinology, April 1, 2005; 146(4): 1863 - 1870. [Abstract] [Full Text] [PDF]

				T. M. Murray, L. G. Rao, P. Divieti, and F. R. Bringhurst Parathyroid Hormone Secretion and Action: Evidence for Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl- Terminal Ligands Endocr. Rev., February 1, 2005; 26(1): 78 - 113. [Abstract] [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, A. Rakel, L. Rousseau, C. Albert, and T. Cantor Evidence That the Amino-Terminal Composition of Non-(1-84) Parathyroid Hormone Fragments Starts before Position 19 Clin. Chem., January 1, 2005; 51(1): 169 - 176. [Abstract] [Full Text] [PDF]

				M. Hayashi, Y. Tsuchiya, Y. Itaya, T. Takenaka, K. Kobayashi, M. Yoshizawa, R. Nakamura, T. Monkawa, and A. Ichihara Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial Nephrol. Dial. Transplant., August 1, 2004; 19(8): 2067 - 2073. [Abstract] [Full Text] [PDF]

				J. J. Kazama, K. Omori, N. Higuchi, N. Takahashi, Y. Ito, H. Maruyama, I. Narita, T. L. Cantor, P. Gao, and F. Gejyo Intact PTH assay overestimates true 1-84 PTH levels after maxacalcitol therapy in dialysis patients with secondary hyperparathyroidism Nephrol. Dial. Transplant., April 1, 2004; 19(4): 892 - 897. [Abstract] [Full Text] [PDF]

				F. R. Bringhurst Circulating Forms of Parathyroid Hormone: Peeling Back the Onion Clin. Chem., December 1, 2003; 49(12): 1973 - 1975. [Full Text] [PDF]

				P. D'Amour, J.-H. Brossard, L. Rousseau, L. Roy, P. Gao, and T. Cantor Amino-Terminal Form of Parathyroid Hormone (PTH) with Immunologic Similarities to hPTH(1-84) Is Overproduced in Primary and Secondary Hyperparathyroidism Clin. Chem., December 1, 2003; 49(12): 2037 - 2044. [Abstract] [Full Text] [PDF]

				A. B. Hodsman, D. A. Hanley, M. P. Ettinger, M. A. Bolognese, J. Fox, A. J. Metcalfe, and R. Lindsay Efficacy and Safety of Human Parathyroid Hormone-(1-84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5212 - 5220. [Abstract] [Full Text] [PDF]

				S. J. Silverberg and J. P. Bilezikian "Incipient" Primary Hyperparathyroidism: A "Forme Fruste" of an Old Disease J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5348 - 5352. [Abstract] [Full Text] [PDF]

				S. J. Silverberg, P. Gao, I. Brown, P. LoGerfo, T. L. Cantor, and J. P. Bilezikian Clinical Utility of an Immunoradiometric Assay for Parathyroid Hormone (1-84) in Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4725 - 4730. [Abstract] [Full Text] [PDF]

				J. C. Estepa, I. Lopez, A. J. Felsenfeld, P. Gao, T. Cantor, M. Rodriguez, and E. Aguilera-Tejero Dynamics of secretion and metabolism of PTH during hypo- and hypercalcaemia in the dog as determined by the 'intact' and 'whole' PTH assays Nephrol. Dial. Transplant., June 1, 2003; 18(6): 1101 - 1107. [Abstract] [Full Text] [PDF]

				H. Reichel, A. Esser, H.-J. Roth, and H. Schmidt-Gayk Influence of PTH assay methodology on differential diagnosis of renal bone disease Nephrol. Dial. Transplant., April 1, 2003; 18(4): 759 - 768. [Abstract] [Full Text] [PDF]

				A. H. Terry, J. Orrock, and A. W. Meikle Comparison of Two Third-Generation Parathyroid Hormone Assays Clin. Chem., February 1, 2003; 49(2): 336 - 337. [Full Text] [PDF]

				W. G. Goodman, I. B. Salusky, and H. Juppner New lessons from old assays: parathyroid hormone (PTH), its receptors, and the potential biological relevance of PTH fragments Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1731 - 1736. [Full Text] [PDF]

				P. Divieti, M. R. John, H. Juppner, and F. R. Bringhurst Human PTH-(7-84) Inhibits Bone Resorption in Vitro Via Actions Independent of the Type 1 PTH/PTHrP Receptor Endocrinology, January 1, 2002; 143(1): 171 - 176. [Abstract] [Full Text] [PDF]